Phase 3 research suggests a significant leap forward in myeloma management
Category: News
Extended phase 2 study highlights macrophage cell therapy’s efficacy
Collaboration yields promising Barriolide therapy Enterothelin
Positive clinical data from phase 1 study presented at ASCO annual meeting
Bone cancer affects more than 150,000 people in the UK and is often resistant to chemotherapy
The platform will be used to diagnose and treat cancers, including lung and brain tumours
The projects will focus on a range of research areas, including Down’s syndrome and ALS
The CVLP platform will speed up access to BioNTech and Genentech’s mRNA personalised cancer vaccines
The first phase of the programme will be in place in hospitals across the UK by March 2025
Affecting the immune system, various forms of SCID are estimated to affect one in 75,000 to 100,000 newborns